Achaogen Announces ACHN-490 Clinical Data at the 49th Annual ICAAC Meeting
9/14/2009 11:24:41 AM
SAN FRANCISCO--(BUSINESS WIRE)--Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug candidate ACHN-490 at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting in San Francisco, CA. ACHN-490 has shown preclinical activity against multi-drug resistant (MDR) Gram-negative and Gram-positive pathogens, and is the most advanced drug in Achaogen’s next-generation aminoglycosides, or neoglycosides.
comments powered by